408 related articles for article (PubMed ID: 19656781)
1. The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility.
Yan L; Li M; Cao Y; Gao P; Cao Y; Wang Y; Jiang Y
J Antimicrob Chemother; 2009 Oct; 64(4):764-73. PubMed ID: 19656781
[TBL] [Abstract][Full Text] [Related]
2. An alternative respiratory pathway on Candida krusei: implications on susceptibility profile and oxidative stress.
Costa-de-Oliveira S; Sampaio-Marques B; Barbosa M; Ricardo E; Pina-Vaz C; Ludovico P; Rodrigues AG
FEMS Yeast Res; 2012 Jun; 12(4):423-9. PubMed ID: 22268592
[TBL] [Abstract][Full Text] [Related]
3. RTA2, a novel gene involved in azole resistance in Candida albicans.
Jia XM; Ma ZP; Jia Y; Gao PH; Zhang JD; Wang Y; Xu YG; Wang L; Cao YY; Cao YB; Zhang LX; Jiang YY
Biochem Biophys Res Commun; 2008 Sep; 373(4):631-6. PubMed ID: 18601908
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation.
Xu Y; Wang Y; Yan L; Liang RM; Dai BD; Tang RJ; Gao PH; Jiang YY
J Proteome Res; 2009 Nov; 8(11):5296-304. PubMed ID: 19754040
[TBL] [Abstract][Full Text] [Related]
5. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.
Ricardo E; Costa-de-Oliveira S; Dias AS; Guerra J; Rodrigues AG; Pina-Vaz C
FEMS Yeast Res; 2009 Jun; 9(4):618-25. PubMed ID: 19416368
[TBL] [Abstract][Full Text] [Related]
6. [Azole resistance in Candida albicans].
Perea S
Rev Esp Quimioter; 2000 Sep; 13(3):314-7. PubMed ID: 11086283
[TBL] [Abstract][Full Text] [Related]
7. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole.
Rautemaa R; Richardson M; Pfaller M; Perheentupa J; Saxen H
Scand J Infect Dis; 2008; 40(11-12):904-7. PubMed ID: 18651265
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of fluconazole on Candida albicans.
Abecia LC; Arévalo JM; López MJ
Microbiologia; 1996 Dec; 12(4):613-20. PubMed ID: 9018696
[TBL] [Abstract][Full Text] [Related]
9. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Rautemaa R; Richardson M; Pfaller M; Koukila-Kähkölä P; Perheentupa J; Saxén H
J Antimicrob Chemother; 2007 Oct; 60(4):889-92. PubMed ID: 17704513
[TBL] [Abstract][Full Text] [Related]
10. The concomitant expression and availability of conventional and alternative, cyanide-insensitive, respiratory pathways in Candida albicans.
Helmerhorst EJ; Stan M; Murphy MP; Sherman F; Oppenheim FG
Mitochondrion; 2005 Jun; 5(3):200-11. PubMed ID: 16050985
[TBL] [Abstract][Full Text] [Related]
11. Tea polyphenol epigallocatechin-3-gallate inhibits ergosterol synthesis by disturbing folic acid metabolism in Candida albicans.
Navarro-Martínez MD; García-Cánovas F; Rodríguez-López JN
J Antimicrob Chemother; 2006 Jun; 57(6):1083-92. PubMed ID: 16585130
[TBL] [Abstract][Full Text] [Related]
12. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves.
Li Y; Sun S; Guo Q; Ma L; Shi C; Su L; Li H
J Antimicrob Chemother; 2008 Mar; 61(3):577-85. PubMed ID: 18194958
[TBL] [Abstract][Full Text] [Related]
13. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
14. Regulation of azole drug susceptibility by Candida albicans protein kinase CK2.
Bruno VM; Mitchell AP
Mol Microbiol; 2005 Apr; 56(2):559-73. PubMed ID: 15813744
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans.
Guo N; Ling G; Liang X; Jin J; Fan J; Qiu J; Song Y; Huang N; Wu X; Wang X; Deng X; Deng X; Yu L
Mycoses; 2011 Sep; 54(5):e400-6. PubMed ID: 21910756
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
17. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
18. Relationship between respiration deficiency and azole resistance in clinical Candida glabrata.
Peng Y; Dong D; Jiang C; Yu B; Wang X; Ji Y
FEMS Yeast Res; 2012 Sep; 12(6):719-27. PubMed ID: 22713096
[TBL] [Abstract][Full Text] [Related]
19. Antifolates as antimycotics? Connection between the folic acid cycle and the ergosterol biosynthesis pathway in Candida albicans.
Navarro-Martínez MD; Cabezas-Herrera J; Rodríguez-López JN
Int J Antimicrob Agents; 2006 Dec; 28(6):560-7. PubMed ID: 17046206
[TBL] [Abstract][Full Text] [Related]
20. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis.
Cernicka J; Subik J
Int J Antimicrob Agents; 2006 May; 27(5):403-8. PubMed ID: 16621465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
